Friday, 20 Oct 2017

You are here

NSAIDs Increase Risk of Acute Myocardial Infarction

Using data from Canadian and European healthcare databases, the BMJ has reported that all NSAIDs, including celecoxib and naproxen, increase the risk of acute myocardial infarction.

While the recent 24,081 patient PRECISION study showed noninferiority between celecoxib, naproxen and ibuprofen with regard to CV risk, that study did not include a placebo arm.

Canadian researchers examined computerised drug prescription or medical databases for the use of selective COX-2 inhibitors (including rofecoxib) and traditional NSAIDs, and looked at the risk of acute myocardial infarction (AMI) in NSAID users with non-users.

 The cohort included 61,460 AMI cases and 385 303 controls (total of 446 763) who were receiving NSAIDs for one week, one month, or more than a month.

The risk of AMI immediately increased with NSAID exposure. Thus, with 1-7 days of NSAID use, AMI risk was significantly increased (with an adjusted odds ratio >1.0) for celecoxib (OR 1.24), ibuprofen (OR 1.48), diclofenac (OR 1.50), naproxen (OR 1.53), and rofecoxib (OR 1.58).

While higher doses were associated with greater risk of myocardial infarction, longer use risk did did exceed risks seen with shorter durations.

Conclusions All NSAIDs, including naproxen, were found to be associated with an increased risk of acute myocardial infarction. Risk of myocardial infarction with celecoxib was comparable to that of traditional NSAIDS and was lower than for rofecoxib. Risk was greatest during the first month of NSAID use and with higher doses.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

1) a meta analysis of observational studies. Not very trustworthy. 2) CONFOUNDING
You hit the nail on the head. This is not novel, new or insightful data. It does little to shed light on a rare association. But because this is getting prominent play in the news, I posted the report for all to be aware, and hopefully look with a discriminating eye; as you have done. Thanks JJC

More Like This

Hepatitis A Outbreak in San Diego

On Sept. 1, 2017, the San Diego County declared a local public health emergency due to the ongoing hepatitis A outbreak in the county.

The outbreak is being spread person-to-person and through contact with fecally contaminated environments. The majority of people who have contracted hepatitis A during this outbreak have been homeless and/or illicit drug users.

Safety of Long-Term PPI Use

The current issue of JAMA reviews the safety of long-term use of proton pump inhibitors (PPI). The following is a collection of the evidence about these purported risks.

Fractures

No Cancer Risk With Biologic Use

A polulation-based study from Sweden has shown that treatment with tocilizumab, abatacept, rituximab, or tumor necrosis factor (TNFi) inhibitors does not affect the risk of malignant neoplasms among patients with rheumatoid arthritis. Specifically, use of a first or second TNFi or biologic DMARDs (bDMARD) does confer a different cancer risk when compared to conventional DMARDS in biologic–naive RA patients.

FDA Panel Backs New Zoster Subunit Vaccine

GlaxoSmithKline has announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted unanimously in support of the efficacy, safety and approval of its herpes zoster subunit (HZ/su) vaccine (called Shingrix) for the prevention of herpes zoster (shingles) in adults ages 50 and over.

New Zoster Vaccine Recommended by FDA Panel

Reuters reports that the FDA advisory panel has voted 11-0 in favor of the safety and efficacy and ultimate approval of GlaxoSmithKline’s Shingrix shingles vaccine for use in adults aged 50 and over.